Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry
Clinical Cardiology · 2023
DOI: 10.1002/clc.24114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Cardiology, 2023. Verfasst von Jingmin Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Hyperkalemia, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Investment China Co., Shanghai, China, National Key Technology Support Program.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Dyskalemia is a mortality risk factor in patients with heart failure (HF). Hypothesis We described the prevalence of dyskalemia, and clinical outcomes by serum potassium (sK) levels, in Chinese patients hospitalized for HF.
Methods
In this secondary analysis of the prospective China National Heart Failure Registry, adult patients hospitalized between January 1, 2013 and June 30, 2015 who had at least one baseline sK measurement were followed for up to 3 years after discharge. The use of renin–angiotensin–aldosterone system inhibitors at baseline and clinical outcomes during follow‐up were compared among sK groups.
Results
Among 6950 patients, 5529 (79.6%) had normokalemia (sK >3.5–5.0 mmol/L), 1113 (16.0%) had hypokalemia (sK 0–3.5 mmol/L), and 308 (4.4%) had hyperkalemia (sK >5.0 mmol/L). Baseline characteristics that were most common in patients with hyperkalemia than those with hypo‐ and normokalemia included older age, HF with reduced ejection fraction, New York Heart Association Class III/IV status, hypertension, and chronic kidney disease. Use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) differed across sK groups ( p = .0001); reported in 64.1%, 63.4%, and 54.5% of patients with hypo‐, normo‐, and hyperkalemia, respectively. Overall, 26.6%, 28.6%, and 36.0% of patients with hypo‐, normo‐, and hyperkalemia had rehospitalization for worsened HF, or cardiovascular mortality; p = .0057 for between‐group comparison.
Conclusions
Patients with hyperkalemia received ACEIs or ARBs for HF treatment at baseline less frequently than those with hypo‐ or normokalemia, and had worse prognoses. This warrants further investigation into effective hyperkalemia management in HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Epidemiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China.
- Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital/Östra Hospital, University of Gothenburg, Gothenburg, Sweden.
ORCID-Profile: Xuejuan Jin
Förderung
- AstraZeneca Investment China Co., Shanghai, China
- National Key Technology Support Program
Zitieren
APA
Zhou, J., Jin, X., Zhou, J., Xu, Y., Cui, X., Fu, M., Hu, K., Ge, J., & CN-HF Investigators (2023). Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry. Clinical Cardiology. https://doi.org/10.1002/clc.24114
Vancouver
Zhou J, Jin X, Zhou J, Xu Y, Cui X, Fu M, et al. Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry. Clinical Cardiology. 2023. doi:10.1002/clc.24114
BibTeX
@article{Zhou2023,
author = {Zhou, Jingmin and Jin, Xuejuan and Zhou, Jun and Xu, Yamei and Cui, Xiaotong and Fu, Michael and Hu, Kai and Ge, Junbo and CN-HF Investigators, CN-HF Investigators},
title = {Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: Secondary analysis of data from the China National Heart Failure Registry},
journal = {Clinical Cardiology},
year = {2023},
doi = {10.1002/clc.24114}
}
EUVIMED